219312-69-3
Chemical Structure
mTRP-2 (180-188)
- CAS No.: 219312-69-3
- Formula:C61H78N10O14
- Molecular Weight:1175.33
IUPAC Name: L-seryl-L-valyl-L-tyrosyl-L-aspartyl-L-phenylalanyl-L-phenylalanyl-L-valyl-L-tryptophyl-L-leucine
InChIKey: DONZTCDLTFZGMF-UKTPXDMFSA-N
SMILES: CC(C)C[C@@H](C(O)=O)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](C(C)C)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC4=CC=CC=C4)NC([C@H](CC(O)=O)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](C(C)C)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
mTRP-2 (180-188) | 99.94% | mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhu X, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of translational medicine. 2007 Feb 12;5:10. [Content Brief]
- [2]. Parkhurst MR, et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer research. 1998 Nov 01;58(21):4895-901. [Content Brief]
- [3]. Schreurs MWJ, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2000;60:6995-7001. [Content Brief]
- [4]. Singh V, et al. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009;32(2):129-39. [Content Brief]
